What Vetter Pharma’s Saarland project reveals about long-cycle CDMO investment strategies
Vetter Pharma commits €480M to build a new commercial injectable manufacturing site in Saarland, Germany; explore industry impact and CDMO capacity shifts.
Pharma & Biotech
Pharma & Biotech
What Quince’s failed NEAT trial reveals about rare pediatric trial design risks
Quince Therapeutics ends clinical development of eDSP for A-T after Phase 3 failure. Find out what this means for its platform and future strategy.
Pharma & Biotech
Is Biocodex’s Fullify the first probiotic to challenge GLP-1 drugs in the consumer weight-loss space?
Biocodex launches Fullify, a gut-brain axis probiotic for appetite control. Find out what this means for weight loss, microbiome science, and the supplement industry.
Pharma & Biotech
How Galderma’s Wake Up To Restylane campaign reflects evolving aesthetics patient preferences
Explore how Galderma’s Wake Up To Restylane strategy and new IMCAS data could reshape aesthetic practice and hyaluronic acid filler adoption.
Pharma & Biotech
Tenpoint’s YUVEZZI sets new benchmark in presbyopia eye drop efficacy and safety
YUVEZZI becomes the first FDA-approved dual-agent eye drop for presbyopia. Find out what this means for Tenpoint Therapeutics and the future of vision care.
Pharma & Biotech
Sinomune to launch Almirall’s Seysara in China: Can it reshape acne treatment models?
Almirall’s Seysara gains NMPA approval for acne in China. Find out what this means for dermatology antibiotics, access, and Sinomune’s market role.
Pharma & Biotech
Sinorda bets on bispecifics with WuXi Biologics for IBD and autoimmune expansion
WuXi Biologics and Sinorda Biomedicine have entered into a strategic collaboration to advance the development and clinical manufacturing of SND006, a novel bispecific antibody targeting inflammatory bowel disease and other autoimmune conditions. The agreement will see Sinorda Biomedicine utilize WuXi Biologics’ CRDMO capabilities to support preclinical development, IND-enabling activities, and global clinical supply for SND006,
Pharma & Biotech
Parkinson’s disease research shifts toward proteoform-level resolution with Nautilus Biotechnology’s platform
Find out how proteoform-level proteomics could transform Parkinson’s biomarker research and reshape future clinical trials.
Pharma & Biotech
Sixty Degrees Pharmaceuticals bets on purification science to unlock castanospermine commercialization
Find out how Sixty Degrees Pharmaceuticals is repositioning castanospermine through a botanical pathway and what regulatory and manufacturing risks still remain.
Pharma & Biotech
Johnson & Johnson expands DARZALEX FASPRO label with new D-VRd approval in newly diagnosed myeloma
Find out how DARZALEX FASPRO’s FDA approval for transplant-ineligible myeloma patients could shift frontline treatment standards.